Pharma Seeks More Guidance On Drug-Induced Liver Injury

Although major pharmaceutical companies do not appear to be rejecting the proposal in FDA's draft guidance on drug-induced liver injury that trials enroll patients with preexisting liver disease, according to comments submitted on the draft, the companies would like to see more clarification on how such patients should be included